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Abstract 
Background and Aim: Multiple lines of evidence have been suggested that JAK2 is likely the main candidate gene 
responsible for the pathogenesis of myeloproliferative neoplasms. The V617F mutation in the pseudokinase domain of 
JAK2 protein has been detected in a majority of patients. We aimed to evaluate the frequency of this somatic missense 
substitution among Iranian patients with myeloproliferative neoplasms. 
Methods Peripheral blood samples were collected from patients with myeloproliferative neoplasms across different 
regions of Iran. The JAK2 V617F mutation was identified by allele-specific PCR. To confirm the PCR results, 
randomly selected positive and negative samples were sequenced. 
Results: Among 72 identified patients, 45 (62.5%) were found to harbor JAK2 V617F. The frequencies of the mutation 
ranged 100% for primary myelofibrosis, 75% for chronic myelogenous leukemia, 67% for polycythemia vera, 62.5% 
for myelodysplastic/myeloproliferative neoplasms, and 52% for essential thrombocythemia. Our findings revealed that 
the mutation was more common among men in comparison with women and the correlation between the mutation and 
gender was statistically significant (p-value<0.01). Additionally, the presence of JAK2 V617F was associated with 
older ages (p-value =0.009). 
Conclusion: The JAK2 V617F mutation was detected in 62.5% of patients with myeloproliferative neoplasms. We 
have shown that this single acquired point mutation was presented in at least half of the patients. Hence, it seems that 
the identification of JAK2 V617F mutation in myeloproliferative neoplasms can be very effective in disease diagnosing 
and management. 
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Introduction 
The myeloproliferative neoplasms (MPNs) are 
hematological malignancies due to clonal 
proliferation of the myeloid cell lineages which 
affect pluripotent hematopoietic stem cells in the 
bone marrow to produce more platelets, red blood 
cells, and white blood cells (1, 2). According to the 
2016 Revised WHO classification, MPNs includes 
eight subcategories: 1) chronic neutrophilic 
leukemia (CNL), 2) chronic myelogenous leukemia 
(CML), 3) polycythemia vera (PV), 4) BCR-ABL1–
positive, 5) primary myelofibrosis (PMF), 6) 
essential thrombocythemia (ET), 7) eosinophilic 
leukemia/hypereosinophilic syndrome (CEL/HES), 
8) mastocytosis (MCD) and unclassifiable MPNs 
(3, 4). 
A single somatic G > T base conversion in exon 12 
of Janus-associated Kinase-2 (JAK2) gene results in 
the amino acid substitution of valine (V) to 
phenylalanine (F) at position 617. This change in 
the pseudokinase domain is thought to alter JAK2 
protein conformation that leads to constitutive 
Janus-associated Kinase- signal transducers and 
activators in the JAK-STAT signaling pathway (5, 
6). JAK2 V617F is occasionally detected in 
leukemia or other bone marrow disorders and 
related disease (7). We don’t know yet how one 
particular mutation can be associated with several 
different conditions (8). Recent studies have shown 
that a significant proportion of non-CML patients 
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have acquired JAK2 V617F. This mutation has a 
variable frequency in different disease conditions 
with the highest percentage in PV samples ranging 
from 65% to 97% (9). The mutation is also found in 
a slightly lower but still substantial percentage of 
ET (30%-57%) and chronic idiopathic 
myelofibrosis (CIMF) (35%-95%) (10, 11). On the 
other hands, JAK2 V617F is relatively uncommon 
in other blood disorders such as typical CML, 
myelodysplasia, acute leukemias without previous 
chronic myeloproliferative diseases (CMPDs), 
chronic myelomonocytic leukemia (CMML), 
chronic lymphocytic leukemia (CLL), and acute 
lymphoblastic leukemia (ALL) (9, 10, 12). In vitro 
and mouse model studies have been shown that 
JAK2 V617F enhances the survival and 
proliferation of BaF3 cells and also increases the 
constitutive phosphorylation of tyrosine, leading to 
cytokine hypersensitivity and erythrocytosis 
stimulation (13-15). Based on these findings, it is 
likely that the JAK2 V617F mutation has an 
important role in the pathogenesis and 
manifestations of these disorders (15). In previous 
studies from Western Europe, North America, and 
Middle-Eastern countries, the frequency of JAK2 
V617F was reported more than 95% in patients with 
PV, and approximately 50% in patients with ET and 
PMF (16, 17). It has been shown previously that 
V617F mutation could be readily detected by AS-
PCR. When the mutant cell population is low, 
detection of the JAK2 V617F mutation using the 
AS-PCR method is easily performable, rapid, 
sensitive, and also cost-effective (18). Hence, here, 
we aimed to estimate the frequency of JAK2 V617F 
mutation in patients with MPNs using AS-PCR. 
Methods 
Participants 
This study was approved by the Ethics Review 
Committee of Pasteur Institute of Iran and 
conducted on patients referred to the Oncology 
Center of Imam Khomeini Hospital from May 2010 
to September 2012. Peripheral blood samples were 
obtained from 112 patients following obtaining 
written informed consent. Forty patients had 
hematological and/or clinical features suggestive 
but not diagnostic of MPN and were excluded from 
the study. Then a total of 72 unrelated patients who 
had an elevated count of platelets, red blood cells, 
and white blood cells were included in the study. 
The patients had a negative test result for BCR-
ABL translocation by either cytogenetic or PCR 
methods. The diagnosis was confirmed according to 
the 2016 World Health Organization (WHO) 
classification (3). 
Molecular Study 
The molecular study was done at the Pasteur 
Institute of Iran. Genomic DNA was extracted by 
the salting-out method. Amplification was done 
using Allele-specific polymerase chain reaction 
(AS-PCR) by two forward and 1 reverse designed 
primers according to the target DNA sequence of 
the JAK2 gene (Table1). 
Table 1. Forward (F) and reverse (R) Primer sequences for AS-PCR and product size 
Allele 
Types 











ATCTATAGTCATGCTGAAAGTAGGAGAAAG 203 bp 
 
PCR reaction was performed in a total volume of 25 
µL containing approximately 25 ng DNA, 12.5 µL 
of PCR Master Mix 2X (Roche, Germany), 0.5 µl 
of each primer.  
The PCR time and temperature program on the 
thermal cycler (Eppendorf) was an initial 
denaturation step at 94°C for 6 min, 40 cycles of 
40 sec. at 94°C, 45 sec. at 56°C, 45 sec. at 72°C, 
and a final extension step of 72°C for 10 min. The 
samples were identified by electrophoresis of the 
AS-PCR products on a 2% agarose gel. To confirm 
the results in the early stages, several positive and 
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negative samples were sequenced by the Sanger 
sequencing method. 
Statistical Analysis 
Statistical analysis was done to determine any 
correlation between mutation and age by t-test. The 
correlation between mutation and sex was analyzed 
by χ2 test. p-value of less than 0.05 was considered 
statistically significant. 
Results 
Using AS-PCR, 45 (62.5%) of 72 patients with 
MPNs, were found to harbor JAK2 V617F 
mutation. The agarose gel electrophoresis and the 
chromatogram of Sanger sequencing results for 
wild and mutant alleles are presented in Figure 1. 
Demographic feature and distribution of JAK2 
V617F mutation 
Demographic features and cancer types in the 
samples are presented in Table 2. The JAK2 V617F 
positive ranged 100 % (2 of 2) for PMF, 75 % (3 of 
4) for CML, 67% (22 of 33) for PV, 62.5% (5 of 8) 
for myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN) and 52% (13 of 25) for ET.  
A summary of these results according to the MPN 
categories is given in Table 3.  
Table 2. Demographic feature and disease subtypes in patients 
Characteristics Number (%) 
Gender (Men/Women) 43(60%)/29(40%) 
Essential thrombocythemia (ET) 25(35%) 
Polycythemia vera (PV) 33(46%) 
Primary myelofibrosis (PMF) 2(3%) 








Figure 1. Identification of the JAK2 V617F mutation by AS-PCR and DNA sequencing methods. A) Gel electrophoresis 
result; 1: Wild type, 2: Mutant type, 3: Wild type, M: 100 bp DNA marker, 4: Negative control, 5: Positive control. B) 
Sanger sequencing results; Up one is related to wild type sequence, down one is related to the mutant type sequence. 
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Table 3. Incidence of JAK2 V617F mutation in patients with MPN, and gender-related distribution of JAK2V617F 
mutation in different disease subtypes 
Subtype of disease 
Number of 
patients 
JAK 2 positive (%) 
Gender in JAK2 
positive patients 
(Men/Women) 
Chronic myelogenous leukemia 
(CML) 
4 3 (75%) 3/0 
Polycythemia vera (PV) 33 22 (67%) 14/8 
Essential thrombocythemia (ET) 25 13 (52%) 7/6 
Primary myelofibrosis (PMF) 2 2 (100%) 1/1 
Myelodysplastic/myeloproliferative 
neoplasms (MDS/MPN) 
8 5 (67%) 4/1 
Total 72 45 (62.5%) 29/16 (64%/36%) 
 
Gender-related distribution of JAK2V617F 
mutation 
The JAK2 V617F mutation was more common 
among men in comparison with women (29 out of 
45 mutation-positive patients were men). The 
correlation between JAK2 V617F and gender was 
statistically significant (p-value <0.01; Table 3).  
The median age of positive patients with MPNs was 
53.2±18.7 years and that of the JAK2 V617F 
negative was 41.2±16.7 years. The presence of the 
mutation was associated with higher age (p-value 
=0.009). We found this mutation not only in the PV, 
ET, and PMF but also in patients with MDS/MPN. 
Discussion 
Multiple lines of evidence have been suggested that 
JAK2 is likely the main candidate gene responsible 
for the pathogenesis of MPN (19). Patients with 
JAK2 V617F mutation in their hematopoietic cells 
respond well to signal transduction therapy. 
Therefore, it is very important to diagnose this 
mutation in patients with MPNs (20). JAK2 V617F 
mutation does not happen in all MPNs which could 
be count as an advantage in distinguishing patients 
with a true primary malignancy from those patients 
with hematological profiles and other clinical 
features, such as erythrocytosis or thrombocytosis 
(21). 
In the current study, the prevalence of the JAK2 
V617F mutation in patients with MPNs was high, 
which maybe the result of the small sample size. 
However, our results were inconsistent with the 
findings of several previous studies (22, 23).  
Since 2005, JAK2 V617F has been detected and 
reported in different CMPDs. There are some case 
report publications claimed the presence of JAK2 
V617F mutation in CML (24). However, 
Murugesan et al. (2006) did not detect JAK2 V617F 
mutation in patients with CML and Non–
Myeloproliferative disorders (12). On the other 
hand, in the study performed by Pahore et al. 
(2010), 26.7% of CML patients had shown the 
presence of JAK2 V617F mutation (24). 
Karimzadeh et al. (2011) reported that 19% of CML 
patients carrying JAK2 V617F (25). In general, it 
seems that the high frequency of JAK2 V617F 
mutation in CML patients in the current study 
(about 75%), was in contrast with previous research 
that showed this mutation rarely occurred in CML. 
The high frequency of JAK2 V617F harboring 
patients with CML may be due to the sample size 
and analytics method related to bias.  
Previous studies have been reported the frequency 
of JAK2 V617F mutation in patients with ET in a 
range between 25 to 50 %. In the reports by Baxter 
et al. (26) and Kralovics et al. (27) JAK2 V617F 
frequency in patients with ET was 57% and 23%, 
respectively. These findings were confirmed by 
subsequent studies (28, 29). In the present study, 
the frequency of JAK2 V617F in patients with ET 
was 52 % which is in coincidence with previous 
studies (30). 
Although the number of PV patients examined in 
the current study was relatively high, the JAK2 
V617F mutation in our PV patients has a lower 
frequency compared to previous studies (n=22, 
67%) (31, 32). This discordance may be related to 
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ethnic variation. This statistical deviation maybe 
corrected by selecting a larger sample size.  
Also in the current study, the frequency of V617F 
mutation in patients with PMF was estimated using 
allele-specific PCR method to be 100 %. This high-
frequency yield maybe the sample size and 
analytics method related to bias.  
Previous surveys have shown that V617F mutation 
could be found in one-third of MDS/MPN patients. 
For example, Langabeer et al (2007) reported that 
33% of patients with MDS/MPN had V617F 
mutation (33). We found here 67% of our 
MDS/MPN patients carrying V617F variation. This 
discordance may be due to a higher number of 
studied patients and higher sensitivity of clinical 
criteria used for diagnosis.  
The JAK2 V617F was much more frequent in men 
than in women patients in the present study. This 
finding is not incompatible with other reports, in 
which the proportion of women with JAK2 V617F 
mutation was higher than men (34). In another 
study with the same sample size, the frequency of 
JAK2 V617F mutation in men and women was 
equal (35). It has been suggested that when 
considering all patients with myeloproliferative 
disorders, allelic burdens are significantly lower in 
women than in men (36). In addition, the 
prevalence of JAK2 V617F mutation in MPNs was 
associated with a higher age range (P<0.01), 
especially with PV patients. JAK2 V617F mutation 
allelic frequency has a great impact on phenotype 
severity and therapy results in patients with MPNs. 
Several studies have shown that ET and PMF 
patients with positive V617F test results manifested 
with older diagnosis age, higher hemoglobin level, 
and leukocyte count, but also lower platelet number 
(37, 38). In a suggested model, the JAK2 V617F 
allele burden progressively increases alongside 
changes in phenotype, with lower allele burden 
inducing isolated thrombocytosis and higher levels 
being accompanied by increases in hemoglobin 
level, leukocytosis, and splenomegaly, and 
ultimately with the fibrotic transformation(39, 40). 
JAK2 mutation can challenge the treatment process 
of patients with MPNs. A study has proven that 
V617F-positive and negative patients with ET 
responded to treatments in different ways. For 
example, V617F-positive patients are extra 
responsive to Hydroxyurea therapy while are not to 
Anagrelide treatment (40-41). The Hydroxyurea 
treatment outcome is the decreased incidence of 
arterial thrombosis in V617F-positive patients, 
while Anagrelide treatment (plus aspirin in each 
arm) does not have this effect. It is noteworthy that 
such differences in drug effect are not documented 
in V617F-negative patients. These findings 
suggested that Hydroxyurea is a more effective 
treatment compared with Anagrelide in JAK2 
V617F positive ET patients, whereas no significant 
difference, in consequence, is observed between 
these two treatments in V617F-negative ET patients 
(42, 43). This finding cannot be generalized to PV 
and patients with PMF.  
Conclusion 
In summary, our findings suggest that it is essential 
for patients with MPN to have JAK2 V617F 
mutation examined because it is both effective in 
diagnosing and determining subtypes of patients 
that respond better to JAK2 inhibitor therapy (43). 
We have shown that a single acquired point 
mutation in the JAK2 gene is presented in virtually 
most PV and PMF and in about half of ET, CML, 
or patients with MDS-MPN. Therefore, the 
investigations on the relationship between the 
JAK2-V617F mutation and the development of 
disease complications are essential in Iranian 
patients with MPN. 
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